Paper Details

  1. Home
  2. Paper Details

Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

Author: AndreattaKristen, BrarIndira, BrinsonCynthia, ChengAndrew, CustodioJoseph, LiuHui, López-CortésLuis, MartinHal, MillsAnthony, MolinaJean-Michel, PodzamczerDaniel, QuirkErin, RuanePeter, StellbrinkHans-Jürgen, WardDouglas

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Switching virologically suppressed adults with HIV-1 infection from dolutegravir, abacavir, and lamivudine to bictegravir, emtricitabine, and tenofovir alafenamide is a safe and effective option that maintains a high barrier to resistance and provides a simplified regimen.
Paper Details　
Original Abstract of the Article :
Bictegravir, co-formulated with emtricitabine and tenofovir alafenamide, has shown good efficacy and tolerability, and similar bone, renal, and lipid profiles to dolutegravir, abacavir, and lamivudine, in treatment-naive adults with HIV-1 infection, without development of treatment-emergent resistan...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2352-3018(18)30092-4

データ提供：米国国立医学図書館（NLM）

Switching Antiretroviral Regimens: A New Option for HIV Treatment

This research explores the potential of switching [antiretroviral regimens] in [virologically suppressed adults with HIV-1]. The study investigates the efficacy and safety of switching from [dolutegravir, abacavir, and lamivudine] to [bictegravir, emtricitabine, and tenofovir alafenamide] after [48 weeks]. The researchers conducted a [randomized, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial] to compare the two regimens, focusing on [virological suppression, safety, and metabolic outcomes].

A New Approach for Long-Term HIV Management

The study explores the potential of switching [antiretroviral regimens] for [long-term HIV management]. The researchers found that switching to [bictegravir, emtricitabine, and tenofovir alafenamide] was both [effective and safe] in [virologically suppressed adults with HIV-1], offering a new option for patients seeking a change in treatment. Imagine a camel traversing the desert. Just as a camel adapts to the changing landscape, patients with HIV can adjust their treatment regimens to optimize their health and well-being.

Navigating the Treatment Landscape

This research offers valuable insights into the evolving landscape of [HIV treatment]. It highlights the need for ongoing research and development to provide patients with a range of safe and effective treatment options.

Dr.Camel's Conclusion

This study underscores the potential of switching [antiretroviral regimens] in [virologically suppressed adults with HIV-1], providing a new option for patients seeking a change in treatment. It highlights the importance of research and development in finding innovative solutions for long-term HIV management.
Date :
  1. Date Completed 2019-01-30
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

29925489

DOI: Digital Object Identifier

10.1016/S2352-3018(18)30092-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.